ethyl glucuronide has been researched along with naltrexone in 2 studies
| Studies (ethyl glucuronide) | Trials (ethyl glucuronide) | Recent Studies (post-2010) (ethyl glucuronide) | Studies (naltrexone) | Trials (naltrexone) | Recent Studies (post-2010) (naltrexone) |
|---|---|---|---|---|---|
| 514 | 28 | 350 | 8,745 | 1,228 | 2,642 |
| Protein | Taxonomy | ethyl glucuronide (IC50) | naltrexone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0051 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0063 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.006 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.006 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.0319 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0093 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0377 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0076 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collins, SE; Duncan, MH; Jackson, TR; Malone, DK; Ries, RK; Saxon, AJ; Smart, BF | 1 |
| Cheong, JC; Kim, JY; Kim, SY; Shin, DW; Suh, S | 1 |
2 other study(ies) available for ethyl glucuronide and naltrexone
| Article | Year |
|---|---|
Extended-release naltrexone and harm reduction counseling for chronically homeless people with alcohol dependence.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Counseling; Craving; Delayed-Action Preparations; Feasibility Studies; Female; Glucuronates; Harm Reduction; Humans; Ill-Housed Persons; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Treatment Outcome | 2015 |
Monitoring alcohol-use-disorder medication compliance by LC-MS/MS determination of urinary ethyl glucuronide, acamprosate, naltrexone, and 6β-naltrexol using zirconia-based hybrid solid-phase extraction.
Topics: Acamprosate; Alcoholism; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glucuronates; Humans; Medication Adherence; Naltrexone; Solid Phase Extraction; Tandem Mass Spectrometry; Zirconium | 2022 |